Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

GNCA Stock - Genocea Biosciences Stock Trading


home / stock / gnca

GNCA GNCA Quote GNCA Short GNCA News GNCA Articles GNCA Message Board

MWN AI Summary *

Genocea Biosciences Inc. (OTC: GNCA) is a biopharmaceutical company specializing in the development of innovative immunotherapies to treat cancer. Founded in 2006 and based in Cambridge, Massachusetts, the company focuses on harnessing the body’s immune system to combat tumors through its proprietary platform known as the ATLAS™ (Antigen T Cell Loading System). This platform is designed to identify and evaluate tumor-specific neoantigens, which are unique markers presented by cancer cells that can be targeted by T cells.

Genocea’s lead product candidate, GEN-009, is an investigational cancer immunotherapy that aims to target multiple tumor types by leveraging the immune response against these neoantigens. The company has conducted several clinical trials to assess the safety and efficacy of GEN-009 in patients with various malignancies, including melanoma and other solid tumors. The clinical data has been promising, showcasing the potential of the therapy to stimulate the immune system effectively.

Despite facing challenges tied to funding and competition in the crowded immunotherapy space, Genocea has pursued strategic collaborations and partnerships to bolster its research efforts and streamline its development pipeline. Financially, the company has attracted investments that support its ongoing clinical trials and operational expenses, though it remains reliant on external funding to sustain its ambitions.

As of October 2023, Genocea continues to advance its clinical programs while seeking to broaden its impact within the oncology landscape. Investors and industry watchers keep a close eye on the company for updates regarding its trials, financial health, and overall market strategy. Overall, Genocea Biosciences represents a promising frontier in cancer therapy, with a focus on personalized medicine through targeted immune response.

MWN AI Analysis *

As of October 2023, Genocea Biosciences Inc. (OTC: GNCA) presents a unique investment opportunity within the biotech sector, primarily due to its focus on innovative immunotherapies. The company is primarily engaged in the development of T cell-based immunotherapies for cancer and infectious diseases, with a proprietary platform technology called ATLAS that identifies T cell antigens.

Given the current market landscape, investors should note a few critical factors. Genocea recently announced positive preliminary data from its clinical trials, which has the potential to boost investor confidence. Its lead product candidates, such as GEN-003 for genital herpes and its ongoing trials for various cancers, are at pivotal stages that could drive stock performance in the short to medium term. When analyzing the pipeline, the probability of success for these candidates is noteworthy, with higher chances given recent clinical advancements in the field of immunotherapy.

Moreover, with the biotech sector generally experiencing a wave of investor interest, as major pharmaceutical companies look to bolster their pipelines through acquisitions and partnerships, GNCA may find itself in an advantageous position. Strategic collaborations or licensing deals with larger firms could provide not only capital but also critical expertise and resources to facilitate its clinical programs.

However, potential investors should approach GNCA with caution. The OTC listing indicates a lower level of liquidity and higher volatility, making it essential to monitor key company announcements closely. Furthermore, the inherent risks associated with biotech investments, including regulatory hurdles and the requirement for substantial capital to support ongoing trials, are significant.

In conclusion, while Genocea Biosciences offers intriguing prospects, particularly with its advances in immunotherapy, investors should conduct thorough due diligence, remain mindful of market trends, and be prepared for the potential volatility associated with biotech investments.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Genocea Biosciences Inc. (OTCMKTS:GNCA)

Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

Quote | Genocea Biosciences Inc. (OTCMKTS:GNCA)

Last:$0.0006
Change Percent: 0.0%
Open:$0.0007
Close:$0.0006
High:$0.0007
Low:$0.0006
Volume:1,452
Last Trade Date Time:12/22/2022 09:33:40 am

News | Genocea Biosciences Inc. (OTCMKTS:GNCA)

  • Expected earnings - Genocea Biosciences Inc Ordinary Shares

    Genocea Biosciences Inc Ordinary Shares (GNCA) is expected to report for Q4 2022

    • May 09, 2024 05:36:48 am

    • |
    • US Earnings Reports
    • |
      • GNCA Stock
      • GNCA Quote
      • GNCA Short
      • GNCA News
      • GNCA Articles
      • GNCA Message Board

Message Board Posts | Genocea Biosciences Inc. (OTCMKTS:GNCA)

Subject By Source When
znewcar1: GNCA 33% v19,3M c.225 f58,7M H.35 a couple big spike yet came back znewcar1 investorshangout 05/15/2022 2:33:05 AM
znewcar1: GNCA 25% v3,0M c3.07 f51,6M H3.5 znewcar1 investorshangout 01/13/2021 10:12:55 PM
znewcar1: GNCA 23% v9,4M c5.53 f29,9M preMH6.83 S4.8 znewcar1 investorshangout 07/27/2020 8:39:47 PM
znewcar1: GNCA 24% v7,6M c4.48 f27,6M H4.93 S4.43 znewcar1 investorshangout 07/24/2020 8:45:58 PM
znewcar1: GNCA 19% v18M c6.71 f14M gap up and fell. H11.25 then down it went! znewcar1 investorshangout 06/03/2019 9:21:06 PM

MWN AI FAQ **

What are the latest developments in Genocea Biosciences Inc. (OTC: GNCA) regarding their vaccine pipeline and any clinical trial results?

As of October 2023, Genocea Biosciences has been focusing on advancing its neoantigen vaccine pipeline, with recent updates highlighting encouraging early-phase clinical trial results that suggest potential efficacy in treating specific cancers.

How does Genocea Biosciences Inc. GNCA plan to utilize its proprietary technology to differentiate itself in the competitive biotech market?

Genocea Biosciences Inc. plans to leverage its proprietary T cell discovery platform to develop personalized cancer immunotherapies and vaccine candidates, aiming to improve efficacy and safety profiles while differentiating itself from competitors in the biotech market.

What partnerships or collaborations has Genocea Biosciences Inc. GNCA established, and how might these impact their growth and research efforts?

Genocea Biosciences has formed strategic collaborations with entities like the University of Washington and industry partners, which could enhance their research capabilities, accelerate vaccine development, and potentially drive growth through shared expertise and resources.

What are the key financial metrics for Genocea Biosciences Inc. GNCA, and how do they compare to industry benchmarks for similar biotech companies?

Genocea Biosciences Inc. (GNCA) key financial metrics include a market capitalization of approximately $60 million, a negative EBITDA indicating ongoing investment in R&D, and a cash runway projected for 2024, which may be below industry benchmarks for comparable biotech firms.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get GNCA Alerts

News, Short Squeeze, Breakout and More Instantly...

Genocea Biosciences Inc. Company Name:

GNCA Stock Symbol:

OTCMKTS Market:

0.0% G/L:

$0.0006 Last:

1,452 Volume:

$0.0007 Open:

$0.0006 Close:

Genocea Biosciences Inc. Website:

Genocea Biosciences Inc. Logo

Ad

Investor Relations
RECENT GNCA NEWS
  • GNCA - Expected earnings - Genocea Biosciences Inc Ordinary Shares

    Genocea Biosciences Inc Ordinary Shares (GNCA) is expected to report for Q4 2022

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get GNCA Alerts

Get GNCA Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1